Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial-Reference-Cited by-同舟云学术

Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial

Published:2017-11-21 Issue:11 Volume:12 Page:e0187393
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Rossetti Barbara^ORCID,Gagliardini Roberta,Meini Genny,Sterrantino Gaetana,Colangeli Vincenzo,Re Maria Carla,Latini Alessandra,Colafigli Manuela,Vignale Francesca,Rusconi Stefano,Micheli Valeria,Di Biagio Antonio,Orofino Giancarlo,Ghisetti Valeria,Fantauzzi Alessandra,Vullo Vincenzo,Grima Pierfrancesco,Francisci Daniela,Mastroianni Claudio,Antinori Andrea,Trezzi Michele,Lisi Lucia,Navarra Pierluigi,Canovari Benedetta,D’Arminio Monforte Antonella,Lamonica Silvia,D’Avino Alessandro,Zazzi Maurizio,Di Giambenedetto Simona,De Luca Andrea,

Funder

Programma Nazionale AIDS project number 40H94

Janssen Europe provided Darunavir tablets for patients in the study arm and supported the pharmacovigilance of the study

ViiV Healthcare Italy supported tropism testing for all patients

ViiV Healthcare Italy supported plasma antiretroviral drug monitoring for patients in the study arm

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference35 articles.

1. Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy;MJ Mugavero;Clin Infect Dis,2011

2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services; January 28, 2016. (17 Jun 2017, date last accessed).

3. European AIDS Clinical Society (EACS). Guidelines: Clinical Management and Treatment of HIV Infected Adults in Europe, Prevention and Management of Non-Infectious Comorbidities in HIV, Version 8.2, January 2017. http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EACSGuidelines-v8.2-English-Jan2017.pdf (17 Jun 2017, date last accessed).

4. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2016. Recommendations of the International Antiviral Society-USA Panel;JAMA,2016

5. Tenofovir and bone health;PM Grant;Curr Opin HIV AIDS,2016

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gene-editing of CCR5 for the Treatment of HIV: A Novel Therapeutic Approach;Turkish Journal of Immunology;2022-04-26

2. Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort;Infectious Diseases and Therapy;2022-04-11

3. Evaluating fostemsavir as a therapeutic option for patients with HIV;Expert Opinion on Pharmacotherapy;2021-06-14

4. Risks and benefits of reducing the number of drugs to treat HIV-1 infection;Expert Opinion on Drug Safety;2021-02-24

5. Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells;Journal of General Virology;2021-01-01